Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects with Metastatic or Locally Advanced Urothelial Cancer

The purpose of this study is to see whether taking the drug Erdafitinib and the drug JNJ-63723283 is safe and effective in treating patients with advanced bladder cancer.
Kathleen Rizzo at or 717-531-0003, ext=289630
18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
≥18 years of age.
Histologic demonstration of transitional cell carcinoma of the urothelium.
Stage IV disease (metastatic or Locally Advanced cT4b, N+, or M+ cancer).
Meet appropriate molecular eligibility criteria
Documented progression of disease per RECIST 1.1, defined as any progression that requires a change in treatment, prior to randomization.
Exclusion Criteria:
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to Cycle 1 Day 1. For Phase 1b, subjects who have received the following prior antitumor therapy
Chemotherapy within 3 weeks of Cycle 1 Day 1
Prior anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy
Active malignancies (ie, requiring treatment change in the last 24 months) other than urothelial cancer (except skin cancers within the last 24 months that are considered completely cured).
Symptomatic central nervous system metastases.
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Hershey, PA